Provided by Tiger Trade Technology Pte. Ltd.

Dermata Therapeutics Inc

1.83
+0.06003.39%
Post-market: 1.82-0.0089-0.49%19:59 EST
Volume:183.97K
Turnover:337.86K
Market Cap:5.19M
PE:-0.15
High:1.95
Open:1.78
Low:1.76
Close:1.77
52wk High:23.70
52wk Low:1.58
Shares:2.84M
Float Shares:1.98M
Volume Ratio:0.39
T/O Rate:9.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.1295
EPS(LYR):-80.3223
ROE:-203.36%
ROA:-96.45%
PB:1.31
PE(LYR):-0.02

Loading ...

Dermata Therapeutics files to sell 1.48M shares of common stock for holders

TIPRANKS
·
Jan 23

Dermata Therapeutics Granted Australian Patent for Spongilla-Based Acne Treatment

Reuters
·
Jan 20

Dermata Therapeutics Announces $12.4 Million Private Placement With Warrants and Share Issuance

Reuters
·
Dec 30, 2025

Top Midday Decliners

MT Newswires Live
·
Dec 27, 2025

Why Is Dermata Therapeutics Stock Surging Wednesday?

Benzinga_recent_news
·
Dec 25, 2025

Dermata Therapeutics: Strategic Shift and Financial Stability Support Buy Rating

TIPRANKS
·
Nov 26, 2025

BRIEF-Dermata Therapeutics Inc Files For Mixed Shelf Of Up To $100 Million

Reuters
·
Nov 25, 2025

Dermata Therapeutics files $100M mixed securities shelf

TIPRANKS
·
Nov 25, 2025

BRIEF-Dermata Therapeutics terminates license agreement with Villani dated March 31, 2017, says in SEC Filing

Reuters
·
Nov 18, 2025

Dermata Therapeutics Inc - Termination Linked to Strategic Shift to Otc Skin Care - SEC Filing

THOMSON REUTERS
·
Nov 18, 2025

Dermata Therapeutics : Villani Will Not Be Entitled to Receive Any Further Milestones or Other Payments Due After Termination Date

THOMSON REUTERS
·
Nov 18, 2025

Dermata Therapeutics Inc - on Nov 17, Terminates License Agreement With Villani Dated March 31, 2017 - SEC Filing

THOMSON REUTERS
·
Nov 18, 2025

BRIEF-Dermata Therapeutics Announces Strategic Pivot To OTC Skin Care - SEC Filing

Reuters
·
Nov 15, 2025

Dermata Therapeutics Q3 net loss narrows as R&D expenses fall

Reuters
·
Nov 15, 2025

Dermata Therapeutics Inc - to Launch First Otc Acne Kit Mid-2026 - SEC Filing

THOMSON REUTERS
·
Nov 15, 2025

Dermata Therapeutics Inc - Announces Strategic Pivot to Otc Skin Care - SEC Filing

THOMSON REUTERS
·
Nov 15, 2025

Dermata Therapeutics Announces Strategic Shift to Over-the-Counter Dermatology Market, Plans Mid-2026 Launch of Once-Weekly Acne Kit Featuring Spongilla Technology

Reuters
·
Nov 15, 2025

Dermata Therapeutics Q3 EPS $(1.65) Misses $(1.59) Estimate

Benzinga
·
Nov 15, 2025

Dermata Therapeutics Increases Stock Offering by $1.79M

TIPRANKS
·
Nov 08, 2025

Dermata Therapeutics’ Spongilla Acne Treatment Patent Application Accepted by Australian Patent Office

Reuters
·
Oct 02, 2025